ArticleScientific reports2026
Novel endopeptidase overcoming lysostaphin resistance.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This study reports the discovery and characterization of a novel enzyme, LssR, a member of the M23 family of peptidoglycan hydrolases from Staphylococcus simulans. Three variants of LssR: the full-length protein (LssR_FL), the mature form (LssR_M), and the catalytic domain (LssR_CD) were cloned, overexpressed in a heterologous E. coli system, and purified. The bacteriolytic activities of these variants were systematically evaluated, and optimal conditions were established for each of them. Notably, all variants exhibited robust bacteriolytic activity against live staphylococcal cells, including strains with serine-containing cross-bridges, that typically confer resistance to lysostaphin. To our knowledge, this is the first report of a novel endopeptidase cleaving serine-containing cross-bridges in staphylococcal peptidoglycan, underscoring potential of LssR as a promising antimicrobial agent capable of overcoming possible lysostaphin resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.